Why Is Everyone Talking About Gilead Sciences Stock?

Since the start of the coronavirus pandemic and the race to find a vaccine or treatment for the disease began, a few stocks have consistently made it to the top of the news cycle. Gilead Sciences (NASDAQ: GILD) is one of them. While the broader stock market took a nosedive in March as the coronavirus swept across the globe, Gilead Sciences was one of the very few pharmaceutical companies that remained resistant to the recession.

In fact, Gilead shares rose while other stocks dropped in the bear market plunge. Currently, Gilead stock is priced right around 15% below its 52-week high and 20% above its 52-week low. The company reported excellent first-quarter earnings results at the end of April, with gross revenue up by 5% on a year-over-year basis. Domestic and global sales also received a boost in the first quarter of 2020, with U.S. sales totaling almost $4 billion and sales in other markets reaching $1.4 billion.

As impressive as Gilead's performance has been amid a struggling global economy, this isn't the only reason everyone's been talking about this stock.

Source Fool.com